Disarming myeloid resistance in CAR T therapy

Area of Science:

• Immunology
• Oncology
• Cellular Therapy

Background:

• Chimeric antigen receptor (CAR) T cell therapy shows promise for B cell lymphoma.
• Understanding resistance mechanisms is crucial for improving CAR T cell therapy efficacy.

Purpose of the Study:

• To identify mechanisms of resistance to CAR T cell therapy in B cell lymphoma.
• To evaluate strategies for overcoming this resistance.

Main Methods:

• Identification of specific immune cell populations associated with treatment failure.
• Functional assays to assess CAR T cell activity in the presence of identified cell populations.
• In vivo studies to evaluate the efficacy of CSF1R inhibition.

Main Results:

• A CSF1R-expressing myeloid and monocytic cell population was identified as a key factor in CAR T cell resistance.
• This myeloid population impairs the function of CD19-targeted CAR T cells.
• Inhibition of CSF1R signaling significantly enhanced the efficacy of CAR T cell therapy.

Conclusions:

• CSF1R+ myeloid cells represent a novel mechanism of resistance to CAR T cell therapy in B cell lymphoma.
• Targeting CSF1R offers a promising strategy to enhance CAR T cell therapy outcomes for patients with B cell lymphoma.